$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Continuous Medication Guide: How long to stop taking venetoclax/venetoclax
2026-02-01 22:25:32
Check Details
Are venetoclax and venetoclax the same medicine? what's the difference
2026-02-01 22:25:32
Check Details
Venetoclax anti-CD20 monoclonal antibody combination shows promise in CLL
2026-02-01 22:25:32
Check Details
Real-world study confirms efficacy of Venetoclax alone after BTKi treatment
2026-02-01 22:25:32
Check Details
Applicable groups for larotrectinib
2026-02-01 22:25:32
Check Details
Is the price of larotrectinib expected to drop in 2024?
2026-02-01 22:25:32
Check Details
None
2026-02-01 22:25:32
Check Details
Development and use of larotrectinib
2026-02-01 22:25:32
Check Details
Dosage forms of larotrectinib
2026-02-01 22:25:32
Check Details
Larotrectinib efficacy, role and price
2026-02-01 22:25:32
Check Details
Why is larotrectinib not recommended?
2026-02-01 22:25:32
Check Details
Why is larotrectinib not recommended for lung cancer?
2026-02-01 22:25:32
Check Details
1
2
...
498
499
500
501
502
503
504
...
10239
10240
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Binimetinib + Encorafenib: Dual MEK/BRAF Targeting in BRAF+ Tumors
2
Neratinib Dosing: 240mg Start, Diarrhea Prophylaxis, Hepatic Adjustment
3
Pomalidomide vs Thalidomide: IMiD Generation Gap and MM Use
4
Dasatinib: A BCR-ABL Targeted TKI, Not Conventional Chemo
5
Obeticholic Acid (OCA): FXR Therapy in PBC and Liver Safety Limits
6
Selumetinib and KRAS Mutations: Where the MEK Inhibitor Actually Fits
7
Erdafitinib in Lung Squamous Cell Carcinoma: Indication Boundaries and FGFR Interpretation
8
Eltrombopag: TPO-Receptor Agonist in ITP and Severe Aplastic Anemia
9
Ganaxolone for CDKL5-Related Seizures: GABA-A Modulation, Not a Cure
10
Daraxonrasib (Rasonque): Chemical Identity and RAS Tri-Complex Mechanism
11
Vosoritide Slowing Effect: Not Always Resistance—Check Dose, Adherence, Epiphyses
12
Ramosetron ODT for IBS-D: Gender-Based Dosing and Treatment Review